Valneva (NASDAQ:VALN) Shares Gap Down – Here’s Why

Valneva SE Sponsored ADR (NASDAQ:VALN) shares gapped down before the market opened on Wednesday . The stock had previously closed at $5.76, but opened at $5.58. Valneva shares last traded at $5.8560, with a volume of 13,252 shares traded.

Wall Street Analyst Weigh In

Several brokerages have issued reports on VALN. Wall Street Zen upgraded Valneva from a “strong sell” rating to a “sell” rating in a research note on Saturday. Guggenheim set a $11.00 price objective on Valneva in a report on Thursday, April 16th. Finally, The Goldman Sachs Group lowered Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price objective for the company. in a report on Wednesday, April 22nd. Three research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $11.98.

Valneva Price Performance

The stock has a market capitalization of $562.22 million, a price-to-earnings ratio of -3.17 and a beta of 1.72. The company has a quick ratio of 1.60, a current ratio of 2.14 and a debt-to-equity ratio of 2.14. The business has a 50-day simple moving average of $6.88 and a two-hundred day simple moving average of $8.54.

Valneva (NASDAQ:VALN) last released its earnings results on Tuesday, March 31st. The company reported ($0.42) earnings per share for the quarter. The firm had revenue of $35.77 million during the quarter. Valneva had a negative return on equity of 107.63% and a negative net margin of 88.87%. As a group, research analysts predict that Valneva SE Sponsored ADR will post -1 earnings per share for the current fiscal year.

Institutional Trading of Valneva

A number of hedge funds have recently modified their holdings of VALN. Marex Group plc purchased a new stake in shares of Valneva in the second quarter valued at $64,000. XTX Topco Ltd acquired a new stake in shares of Valneva in the fourth quarter worth about $94,000. JPMorgan Chase & Co. acquired a new stake in shares of Valneva in the third quarter valued at about $124,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Valneva in the fourth quarter valued at about $44,000. Finally, VSM Wealth Advisory LLC lifted its stake in shares of Valneva by 125.0% in the third quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after buying an additional 5,000 shares during the period. Hedge funds and other institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.